CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.98B, above the global median of $1.2B
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%
Annual Rate
INR 2.00Paid unknown
Payout Ratio
19.8%Sustainable
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
478.07BINR4.98B · vs all stocks (USD)
Trailing P/E
85.56xvs Biotechnology peers
Revenue (TTM)
20.07BINR209.18M · vs all stocks (USD)
Profit Margin
28.69%vs Biotechnology peers
52-Week Change
11.81%vs all stocks
Forward Annual Dividend Yield
0.23%vs all stocks
Market Capitalization
478.07BINR4.98B · vs all stocks (USD)
Enterprise Value
481.87BINR5.02B · vs all stocks (USD)
Trailing P/E
85.56xvs Biotechnology peers
Forward P/E
57.34xvs Biotechnology peers
PEG Ratio
1.95xvs Biotechnology peers
Price to Sales (TTM)
24.25xvs Biotechnology peers
Price to Book (MRQ)
16.00xvs Biotechnology peers
Enterprise to Revenue
24.00xvs Biotechnology peers
Enterprise to EBITDA
59.73xvs Biotechnology peers
Gross Margin
65.04%vs Biotechnology peers
Profit Margin
28.69%vs Biotechnology peers
Operating Margin
28.83%vs Biotechnology peers
Return on Assets (TTM)
17.26%vs Biotechnology peers
Return on Equity (TTM)
19.45%vs Biotechnology peers
Revenue (TTM)
20.07BINR209.18M · vs all stocks (USD)
Revenue per Share (TTM)
35.70INRUpdated Sep 29, 2026Quarterly Revenue Growth
-22.60%vs Biotechnology peers
Gross Profit (TTM)
12.38BINR128.98M · vs all stocks (USD)
EBITDA (TTM)
9.51BINR99.08M · vs all stocks (USD)
Net Income (TTM)
5.76BINR60.02M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-11.70%vs Biotechnology peers
Operating Cash Flow (TTM)
8.44BINR88.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.92BINR61.67M · vs all stocks (USD)
Forward Annual Dividend Rate
2.00INRUpdated Sep 29, 2026Forward Annual Dividend Yield
0.23%vs all stocks
Trailing Annual Dividend Rate
0.00INRUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
19.76%vs Biotechnology peers
Revenue
21.24BINRFY2026 · Mar 31, 2026Cost of Goods Sold
8.12BINRFY2026 · Mar 31, 2026Gross Profit
13.12BINRFY2026 · Mar 31, 2026Operating Income
7.05BINR73.49M · vs all stocks (USD)
Pre-tax Income
8.24BINRFY2026 · Mar 31, 2026Income Tax Expense
2.32BINRFY2026 · Mar 31, 2026Net Income
5.92BINRFY2026 · Mar 31, 2026EBIT
8.31BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
9.80BINRFY2026 · Mar 31, 2026Research & Development
181.54MINRFY2026 · Mar 31, 2026Selling, General & Administrative
188.36MINRFY2026 · Mar 31, 2026Other Operating Expenses
1.57BINRFY2026 · Mar 31, 2026Non-operating Interest Income
792.70MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
65.41MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
9.44BINRFY2026 · Mar 31, 2026Free Cash Flow
7.37BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
2.75BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
8.24BINRFY2026 · Mar 31, 2026Stock-based Compensation
158.59MINRFY2026 · Mar 31, 2026Other Non-cash Items
-723.76MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.26BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
3.02BINRFY2026 · Mar 31, 2026Capital Expenditures
-2.07BINRFY2026 · Mar 31, 2026Purchase of Investments
-5.78BINRFY2026 · Mar 31, 2026Sale of Investments
87.96MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-7.77BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-192.94MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-385.93MINRFY2026 · Mar 31, 2026Other Financing Charges
170.00KINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-313.05MINRFY2026 · Mar 31, 2026Shares Outstanding
561.71MSharesUpdated Sep 29, 2026Float Shares
71.88MSharesUpdated Sep 29, 2026% Held by Insiders
83.97%vs all stocks
% Held by Institutions
12.88%vs all stocks
Total Cash (MRQ)
9.38BINR97.80M · vs all stocks (USD)
Total Cash per Share (MRQ)
16.71INRUpdated Sep 29, 2026Total Debt (MRQ)
539.24MINR5.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0177xvs Biotechnology peers
Current Ratio (MRQ)
5.54xvs Biotechnology peers
Book Value per Share (MRQ)
54.16INRUpdated Sep 29, 2026Total Assets
34.29BINR357.37M · vs all stocks (USD)
Total Current Assets
18.03BINRFY2026 · Mar 31, 2026Total Liabilities
3.87BINRFY2026 · Mar 31, 2026Total Non-current Assets
16.26BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
610.60MINRFY2026 · Mar 31, 2026Total Current Liabilities
3.26BINRFY2026 · Mar 31, 2026Cash
169.85MINRFY2026 · Mar 31, 2026Cash Equivalents
2.56BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
2.73BINRFY2026 · Mar 31, 2026Other Short-term Investments
6.66BINRFY2026 · Mar 31, 2026Accounts Receivable
5.91BINRFY2026 · Mar 31, 2026Inventory
1.25BINRFY2026 · Mar 31, 2026Accounts Payable
791.59MINRFY2026 · Mar 31, 2026Short-term Debt
253.07MINRFY2026 · Mar 31, 2026Other Current Liabilities
1.63BINRFY2026 · Mar 31, 2026Long-term Debt
286.17MINRFY2026 · Mar 31, 2026Other Non-current Liabilities
-10.00KINRFY2026 · Mar 31, 2026Common Stock (Book)
1.12BINRFY2026 · Mar 31, 2026Retained Earnings
24.55BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
30.43BINR317.06M · vs all stocks (USD)
52-Week Low
579.15INRUpdated Sep 29, 202652-Week High
977.55INRUpdated Sep 29, 202652-Week Change
11.81%vs all stocks
50-Day MA
875.45INRUpdated Sep 29, 2026200-Day MA
747.67INRUpdated Sep 29, 2026Avg 10-Day Volume
981.84KSharesUpdated Sep 29, 2026Avg 30-Day Volume
863.50KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
10.13INRUpdated Sep 29, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 24.25Revenue Growth YoY: -0.23
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.98B, above the global median of $1.2BNotable
Market cap (USD): 4,982,015,876.629Global Median: 1,201,862,193
Levered free cash flow is $61.67M, above the global median of $18.92MNotable
Levered free cash flow (USD): 61,670,644.32Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Humanwell Healthcare Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
GenScript Biotech Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Ligand Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Medpace Holdings Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Sezzle Inc.
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthDown-Close Streak With ProfitabilityIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
NVIDIA Corporation
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated